POM-V
Prescription Required
Companion Animal
Baytril 50 mg/ml Solution for Injection
Active ingredient: Enrofloxacin
Form
Injection
Species
Cats
Cattle
Dogs
Goats
Pigs
Sheep
Manufacturer
Elanco GmbH
VMD MA No.
52127/5120
What it's used for
Treatment of infections of the respiratory tract caused by enrofloxacin susceptible strains of Pasteurella multocida, Mannheimia haemolytica and Mycoplasma...
Full indications, dosage and side effects ↓The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.
Paying less for Enrofloxacin
-
1
Ask your vet for a written prescription
They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
-
2
Fill it at a registered online retailer
The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.
Done — we'll email you when prices land.
Prescription required
Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.
Clinical information
Baytril 50 mg/ml Solution for Injection — SPC Details
Source: VMD Summary of Product Characteristics (SPC). Last updated 18 Mar 2026.
Treatment of infections of the respiratory tract caused by enrofloxacin
susceptible strains of Pasteurella multocida, Mannheimia haemolytica and
Mycoplasma spp.
Treatment of infections of the alimentary tract caused by enrofloxacin
susceptible strains of Escherichia coli.
Treatment of septicaemia caused by enrofloxacin susceptible strains of
Escherichia coli.
Treatment of acute mycoplasma-associated arthritis due to enrofloxacin
susceptible strains of Mycoplasma bovis
Sheep
Treatment of infections of the alimentary tract caused by enrofloxacin
susceptible strains of Escherichia coli.
Treatment of septicaemia caused by enrofloxacin susceptible strains of
Escherichia coli.
Treatment of mastitis caused by enrofloxacin susceptible strains of
Staphylococcus aureus and
Revised: September 2025
AN: 01467/2025
Goats
Treatment of infections of the respiratory tract caused by enrofloxacin
susceptible strains of Pasteurella multocida and .
Treatment of infections of the alimentary tract caused by enrofloxacin
susceptible strains of Escherichia coli.
Treatment of septicaemia caused by enrofloxacin susceptible strains of
Escherichia coli.
Treatment of mastitis caused by enrofloxacin susceptible strains of
Staphylococcus aureus and
Pigs
Treatment of infections of the respiratory tract caused by enrofloxacin
susceptible strains of Pasteurella multocida, Mycoplasma spp. and
Actinobacillus pleuropneumoniae.
Treatment of infections of the alimentary tract caused by enrofloxacin
susceptible strains of Escherichia coli.
Treatment of septicaemia caused by enrofloxacin susceptible strains of
Escherichia coli.
Dogs
Treatment of infections of the alimentary, respiratory and urogenital tracts
(including prostatitis, adjunctive antibiotic therapy for pyometra), skin and
wound infections, otitis (externa/media) caused by enrofloxacin susceptible
strains of Staphylococcus spp., Escherichia coli, Pasteurella spp
spp., Bordetella spp., Pseudomonas Proteus spp.
Cats
Treatment of infections of the alimentary, respiratory and urogenital tracts
(as adjunctive antibiotic therapy for pyometra), skin and wound infections,
caused by enrofloxacin susceptible strains of, e.g.: Staphylococcus
Escherichia coli, Pasteurella spp., Klebsiella spp., Bordetella spp
Pseudomonas spp. and Proteus spp
susceptible strains of Pasteurella multocida, Mannheimia haemolytica and
Mycoplasma spp.
Treatment of infections of the alimentary tract caused by enrofloxacin
susceptible strains of Escherichia coli.
Treatment of septicaemia caused by enrofloxacin susceptible strains of
Escherichia coli.
Treatment of acute mycoplasma-associated arthritis due to enrofloxacin
susceptible strains of Mycoplasma bovis
Sheep
Treatment of infections of the alimentary tract caused by enrofloxacin
susceptible strains of Escherichia coli.
Treatment of septicaemia caused by enrofloxacin susceptible strains of
Escherichia coli.
Treatment of mastitis caused by enrofloxacin susceptible strains of
Staphylococcus aureus and
Revised: September 2025
AN: 01467/2025
Goats
Treatment of infections of the respiratory tract caused by enrofloxacin
susceptible strains of Pasteurella multocida and .
Treatment of infections of the alimentary tract caused by enrofloxacin
susceptible strains of Escherichia coli.
Treatment of septicaemia caused by enrofloxacin susceptible strains of
Escherichia coli.
Treatment of mastitis caused by enrofloxacin susceptible strains of
Staphylococcus aureus and
Pigs
Treatment of infections of the respiratory tract caused by enrofloxacin
susceptible strains of Pasteurella multocida, Mycoplasma spp. and
Actinobacillus pleuropneumoniae.
Treatment of infections of the alimentary tract caused by enrofloxacin
susceptible strains of Escherichia coli.
Treatment of septicaemia caused by enrofloxacin susceptible strains of
Escherichia coli.
Dogs
Treatment of infections of the alimentary, respiratory and urogenital tracts
(including prostatitis, adjunctive antibiotic therapy for pyometra), skin and
wound infections, otitis (externa/media) caused by enrofloxacin susceptible
strains of Staphylococcus spp., Escherichia coli, Pasteurella spp
spp., Bordetella spp., Pseudomonas Proteus spp.
Cats
Treatment of infections of the alimentary, respiratory and urogenital tracts
(as adjunctive antibiotic therapy for pyometra), skin and wound infections,
caused by enrofloxacin susceptible strains of, e.g.: Staphylococcus
Escherichia coli, Pasteurella spp., Klebsiella spp., Bordetella spp
Pseudomonas spp. and Proteus spp
Intravenous, subcutaneous or intramuscular use.
Repeated injections should be made at different injection sites.
To ensure a correct dosage, body weight (bw) should be determined as
accurately as possible to avoid underdosing.
Calves
5 mg of enrofloxacin/kg bw, corresponding to 1 ml/10 kg bw, once daily for
3-5 days.
Acute mycoplasma-associated arthritis due to enrofloxacin susceptible
strains of Mycoplasma bovis: 5 mg of enrofloxacin/kg bw, corresponding to
1 ml/10 kg bw, once daily for 5 days.
The product can be administered by slow intravenous or subcutaneous
administration.
Not more than 10 ml should be administered at one subcutaneous injection
site.
Sheep and goats
5 mg of enrofloxacin/kg bw, corresponding to 1 ml/10 kg bw, once daily by
subcutaneous injection for 3 days.
Not more than 6 ml should be administered at one subcutaneous injection
site.
Pigs
2.5 mg of enrofloxacin/kg bw, corresponding to 0.5 ml/10 kg bw, once daily
by intramuscular injection for 3 days.
Alimentary tract infection or septicaemia caused by Escherichia coli: 5 mg of
enrofloxacin/kg bw, corresponding to 1 ml/10 kg bw, once daily by
intramuscular injection for 3 days.
In pigs, the injection should be made in the neck at the ear base.
Not more than 3 ml should be administered at one intramuscular injection
site.
Dogs and cats
5 mg of enrofloxacin/kg bw, corresponding to 1 ml/10 kg bw, once daily by
subcutaneous injection for up to 5 days.
Revised: September 2025
AN: 01467/2025
Treatment may be initiated with injectable product and maintained with
enrofloxacin tablets. Duration of treatment should be based on the duration
of treatment approved for the appropriate indication in the product
information of the tablet product.
Repeated injections should be made at different injection sites.
To ensure a correct dosage, body weight (bw) should be determined as
accurately as possible to avoid underdosing.
Calves
5 mg of enrofloxacin/kg bw, corresponding to 1 ml/10 kg bw, once daily for
3-5 days.
Acute mycoplasma-associated arthritis due to enrofloxacin susceptible
strains of Mycoplasma bovis: 5 mg of enrofloxacin/kg bw, corresponding to
1 ml/10 kg bw, once daily for 5 days.
The product can be administered by slow intravenous or subcutaneous
administration.
Not more than 10 ml should be administered at one subcutaneous injection
site.
Sheep and goats
5 mg of enrofloxacin/kg bw, corresponding to 1 ml/10 kg bw, once daily by
subcutaneous injection for 3 days.
Not more than 6 ml should be administered at one subcutaneous injection
site.
Pigs
2.5 mg of enrofloxacin/kg bw, corresponding to 0.5 ml/10 kg bw, once daily
by intramuscular injection for 3 days.
Alimentary tract infection or septicaemia caused by Escherichia coli: 5 mg of
enrofloxacin/kg bw, corresponding to 1 ml/10 kg bw, once daily by
intramuscular injection for 3 days.
In pigs, the injection should be made in the neck at the ear base.
Not more than 3 ml should be administered at one intramuscular injection
site.
Dogs and cats
5 mg of enrofloxacin/kg bw, corresponding to 1 ml/10 kg bw, once daily by
subcutaneous injection for up to 5 days.
Revised: September 2025
AN: 01467/2025
Treatment may be initiated with injectable product and maintained with
enrofloxacin tablets. Duration of treatment should be based on the duration
of treatment approved for the appropriate indication in the product
information of the tablet product.
Do not use in animals with known hypersensitivity to enrofloxacin or other
fluoroquinolones or to any of the excipients.
Do not use in animals that are epileptic or suffer from seizures since
enrofloxacin may cause CNS stimulation.
Do not use in young dogs during their growth, i.e. in small breeds of dogs
less than 8 months of age, in big breeds of dogs less than 12 months of age,
in giant breeds of dogs less than 18 months of age.
Do not use in cats less than 8 weeks of age.
Do not use in growing horses because of possible deleterious damage on
articular cartilage.
Revised: September 2025
AN: 01467/2025
fluoroquinolones or to any of the excipients.
Do not use in animals that are epileptic or suffer from seizures since
enrofloxacin may cause CNS stimulation.
Do not use in young dogs during their growth, i.e. in small breeds of dogs
less than 8 months of age, in big breeds of dogs less than 12 months of age,
in giant breeds of dogs less than 18 months of age.
Do not use in cats less than 8 weeks of age.
Do not use in growing horses because of possible deleterious damage on
articular cartilage.
Revised: September 2025
AN: 01467/2025
Digestive tract disorders (e.g. diarrhoea) may occur in very rare cases.
These signs are generally mild and transient.
In very rare cases, neurological signs (seizures, tremors, ataxia, excitation)
and anaphylactic reactions can also occur.
Local reactions at injection site
In calves, transient local tissue reactions may occur in very rare cases and
may be observed up to 14 days.
In pigs, after intramuscular administration of the product, inflammatory
reactions may occur. They may persist up to 28 days after the injection In
dogs, a moderate and transient local reaction (such as oedema) may occur.
The frequency of adverse reactions is defined using the following
convention:
- very common (more than 1 in 10 animals displaying adverse
reactions during the course of one treatment)
- common (more than 1 but less than 10 animals in 100 animals)
- uncommon (more than 1 but less than 10 animals in 1,000 animals)
- rare (more than 1 but less than 10 animals in 10,000 animals)
- very rare (less than 1 animal in 10,000 animals, including isolated
reports).
These signs are generally mild and transient.
In very rare cases, neurological signs (seizures, tremors, ataxia, excitation)
and anaphylactic reactions can also occur.
Local reactions at injection site
In calves, transient local tissue reactions may occur in very rare cases and
may be observed up to 14 days.
In pigs, after intramuscular administration of the product, inflammatory
reactions may occur. They may persist up to 28 days after the injection In
dogs, a moderate and transient local reaction (such as oedema) may occur.
The frequency of adverse reactions is defined using the following
convention:
- very common (more than 1 in 10 animals displaying adverse
reactions during the course of one treatment)
- common (more than 1 but less than 10 animals in 100 animals)
- uncommon (more than 1 but less than 10 animals in 1,000 animals)
- rare (more than 1 but less than 10 animals in 10,000 animals)
- very rare (less than 1 animal in 10,000 animals, including isolated
reports).
None
i) Special precautions for use in animals
Official and local antimicrobial policies should be taken into account when
the product is used.
Fluoroquinolones should be reserved for the treatment of clinical conditions
which have responded poorly, or are expected to respond poorly, to other
classes of antimicrobials.
Whenever possible fluoroquinolones should only be used based on
susceptibility testing.
Use of the product including use deviating from the instructions given in the
SPC may increase the prevalence of bacteria resistant to enrofloxacin and
may decrease the effectiveness of treatment with all fluoroquinolones due to
the potential for cross-resistance.
Special caution should be taken when using enrofloxacin in animals with
impaired renal function.
Special caution should be taken when using enrofloxacin in cats because
higher doses than recommended can cause retinal damage and blindness.
For cats weighting less than 5 kg, the dosage of 25 mg/ml is more
appropriate to avoid risk of overdosage (see section 4.10).
Degenerative changes of articular cartilage were observed in calves treated
orally with 30 mg enrofloxacin/kg body weight during 14 days.
The use of enrofloxacin in growing lambs at the recommended dose for 15
days caused histological changes in the articular cartilage, not associated to
clinical signs.
ii) Special precautions to be taken by the person administering the
veterinary medicinal product to animals
Enrofloxacin may cause hypersensitivity (allergic reactions). People with
known hypersensitivity to fluoroquinolones (e.g., enrofloxacin or
ciprofloxacin) should avoid any contact with the product.
The product may be irritant to skin and eyes.
Wear impervious gloves when handling the product.
Wash any splashes from skin or eyes immediately with water.
Wash hands and exposed skin after use.
Do not eat, drink or smoke whilst using the product.
Revised: September 2025
AN: 01467/2025
Care should be taken to avoid accidental self-injection. If accidental self-
injection occurs seek medical advice immediately.
iii) Other precautions
In countries where feeding of fallen stock to scavenger bird populations is
permitted as a conservation measure (see Commission Decision
2003/322/EC), the possible risk to hatching success should be considered
before feeding carcasses of livestock recently treated with this product.
i) Special precautions for use in animals
Official and local antimicrobial policies should be taken into account when
the product is used.
Fluoroquinolones should be reserved for the treatment of clinical conditions
which have responded poorly, or are expected to respond poorly, to other
classes of antimicrobials.
Whenever possible fluoroquinolones should only be used based on
susceptibility testing.
Use of the product including use deviating from the instructions given in the
SPC may increase the prevalence of bacteria resistant to enrofloxacin and
may decrease the effectiveness of treatment with all fluoroquinolones due to
the potential for cross-resistance.
Special caution should be taken when using enrofloxacin in animals with
impaired renal function.
Special caution should be taken when using enrofloxacin in cats because
higher doses than recommended can cause retinal damage and blindness.
For cats weighting less than 5 kg, the dosage of 25 mg/ml is more
appropriate to avoid risk of overdosage (see section 4.10).
Degenerative changes of articular cartilage were observed in calves treated
orally with 30 mg enrofloxacin/kg body weight during 14 days.
The use of enrofloxacin in growing lambs at the recommended dose for 15
days caused histological changes in the articular cartilage, not associated to
clinical signs.
ii) Special precautions to be taken by the person administering the
veterinary medicinal product to animals
Enrofloxacin may cause hypersensitivity (allergic reactions). People with
known hypersensitivity to fluoroquinolones (e.g., enrofloxacin or
ciprofloxacin) should avoid any contact with the product.
The product may be irritant to skin and eyes.
Wear impervious gloves when handling the product.
Wash any splashes from skin or eyes immediately with water.
Wash hands and exposed skin after use.
Do not eat, drink or smoke whilst using the product.
Revised: September 2025
AN: 01467/2025
Care should be taken to avoid accidental self-injection. If accidental self-
injection occurs seek medical advice immediately.
iii) Other precautions
In countries where feeding of fallen stock to scavenger bird populations is
permitted as a conservation measure (see Commission Decision
2003/322/EC), the possible risk to hatching success should be considered
before feeding carcasses of livestock recently treated with this product.
interaction
Do not use enrofloxacin concomitantly with antimicrobial substances acting
antagonistically to quinolones (e.g. macrolides, tetracyclines or phenicols).
Revised: September 2025
AN: 01467/2025
Do not use concurrently with theophylline as the elimination of theophylline
may be delayed.
Care should be taken during the concomitant use of flunixin and
enrofloxacin in dogs to avoid adverse drug reactions. The decrease in drug
clearances as a result of co-administration of flunixin and enrofloxacin
indicates that these substances interact during the elimination phase. Thus,
in dogs, the co-administration of enrofloxacin and flunixin increased the
AUC and the elimination half-life of flunixin and increased the elimination
half-life and reduced the Cmax of enrofloxacin.
Do not use enrofloxacin concomitantly with antimicrobial substances acting
antagonistically to quinolones (e.g. macrolides, tetracyclines or phenicols).
Revised: September 2025
AN: 01467/2025
Do not use concurrently with theophylline as the elimination of theophylline
may be delayed.
Care should be taken during the concomitant use of flunixin and
enrofloxacin in dogs to avoid adverse drug reactions. The decrease in drug
clearances as a result of co-administration of flunixin and enrofloxacin
indicates that these substances interact during the elimination phase. Thus,
in dogs, the co-administration of enrofloxacin and flunixin increased the
AUC and the elimination half-life of flunixin and increased the elimination
half-life and reduced the Cmax of enrofloxacin.
Advice for handling: Do not refrigerate or freeze.
Calves:
Following intravenous injection: Meat and offal: 5 days. Following
subcutaneous injection: Meat and offal: 12 days.
Not authorized for use in animals producing milk for human consumption.
Sheep:
Meat and offal: 4 days. Milk: 3 days.
Goats:
Meat and offal: 6 days. Milk: 4 days.
Pigs:
Meat and offal: 13 days.
5.
Following intravenous injection: Meat and offal: 5 days. Following
subcutaneous injection: Meat and offal: 12 days.
Not authorized for use in animals producing milk for human consumption.
Sheep:
Meat and offal: 4 days. Milk: 3 days.
Goats:
Meat and offal: 6 days. Milk: 4 days.
Pigs:
Meat and offal: 13 days.
5.
This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.
Medication costs adding up?
Pet insurance can cover prescription medications. Find the right policy for your pet.
Related Conditions
Same active ingredient
Other Products Containing Enrofloxacin
These products share the same active ingredient and may be suitable alternatives. Always consult your vet.
Baytril 100 mg/ml Solution for Injection
POM-VElanco GmbH
injection
Cattle
Goats
Pigs
Baytril 100 mg/ml Solution for Injection
POM-VElanco GmbH
injection
Cattle
Goats
Pigs
Baytril 100 mg/ml Solution for use in Drinking Water for Chickens, Turkeys and Rabbits
POM-VElanco GmbH
solution
Chickens
Rabbits
Turkeys
Baytril 100 mg/ml Solution for use in Drinking Water for Chickens, Turkeys and Rabbits
POM-VElanco GmbH
solution
Chickens
Rabbits
Turkeys
Baytril 25 mg/ml Oral Solution
POM-VElanco GmbH
liquid
Cattle
Exotic Animal
Reptiles
Baytril 25 mg/ml Oral Solution
POM-VElanco GmbH
liquid
Cattle
Exotic Animal
Reptiles
Alternative options to consider
Retailers we earn a commission from. It costs you nothing and never changes what we show.
The Pharm Pet Co.
The Pharm Pet Co. — Pet Pharmacy
UK online pet pharmacy. Flea, worm, prescription medications, supplements and pet food. Save vs vet prices.
Save up to 50%
Shop now
Pharmacy2U
Pet Care at Pharmacy2U
The UK's largest online pharmacy. Pet wormers, flea treatments, dental and joint care. Free delivery on orders over £30.
Free delivery £30+
Shop now
Petlibro
Petlibro Automatic Feeder
Smart automatic pet feeder with app control. Schedule meals, portion control, and feeding history.
From £49.99
Shop now
We may earn a small commission if you purchase through these links, at no extra cost to you.
Also in antibiotic
Related Medications
Actionis 50 mg/ml, Suspension for Injection for Pigs and Cattle
POM-VCeftiofur
injection
Rx
Cattle
Pigs
Actionis 50 mg/ml, Suspension for Injection for Pigs and Cattle
POM-VCeftiofur
injection
Rx
Cattle
Pigs
Adaxio Shampoo for Dogs
POM-VChlorhexidine Gluconate + Miconazole Nitrate
shampoo
Rx
Dogs
Adaxio Shampoo for Dogs
POM-VChlorhexidine Gluconate + Miconazole Nitrate
shampoo
Rx
Dogs
Advocin 180, 180 mg/ml, Solution for Injection for Cattle
POM-VDanofloxacin
injection
Rx
Cattle
Aivlosin 42.5 mg/g Oral Powder for Pigs
POM-VTylvalosin
powder
Rx
Pigs
Find cheaper vets near you
Compare vet consultation prices in your area. Save on procedures and get a prescription to buy medications online.